Loading...

Respiri Limited

RSHUFPNK
Healthcare
Medical - Devices
$0.06
$0.00(0.00%)

Respiri Limited (RSHUF) Financial Performance & Income Statement Overview

Explore the financials of Respiri Limited (RSHUF), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
547.80%
547.80%
Operating Income Growth
-10.21%
10.21%
Net Income Growth
-23.44%
23.44%
Operating Cash Flow Growth
-47.91%
47.91%
Operating Margin
-1673.36%
1673.36%
Gross Margin
99.16%
99.16%
Net Profit Margin
-1560.30%
1560.30%
ROE
-411.64%
411.64%
ROIC
-276.54%
276.54%

Respiri Limited (RSHUF) Income Statement & Financial Overview

View the income breakdown for Respiri Limited RSHUF across both annual and quarterly reports.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$309466.00$147448.00$60690.00$9843.00
Cost of Revenue$220.00$2.10M$1.32M$1.20M
Gross Profit$309246.00-$1.95M-$1.25M-$1.19M
Gross Profit Ratio$1.00-$13.23-$20.67-$121.08
R&D Expenses$67367.00$69765.00$48218.00$329507.00
SG&A Expenses$4.21M$1.69M$1.88M$1.65M
Operating Expenses$4.27M$1.76M$1.93M$1.97M
Total Costs & Expenses$4.28M$3.85M$3.25M$3.18M
Interest Income$0.00$1781.00$2804.00$1436.00
Interest Expense$0.00$65015.00$15000.00$0.00
Depreciation & Amortization-$74941.00$89264.00$37259.00$40034.00
EBITDA-$4.01M-$3.58M-$3.15M-$3.13M
EBITDA Ratio-$12.97-$24.53-$51.87-$317.62
Operating Income-$3.97M-$3.71M-$3.19M-$3.17M
Operating Income Ratio-$12.81-$25.13-$52.49-$321.69
Other Income/Expenses (Net)$23890.00-$26635.00-$12198.00$38038.00
Income Before Tax-$3.94M-$3.73M-$3.20M-$3.13M
Income Before Tax Ratio-$12.74-$25.31-$52.69-$317.83
Income Tax Expense$0.00-$545003.00$1.00-$550730.00
Net Income-$3.94M-$3.19M-$3.20M-$2.58M
Net Income Ratio-$12.74-$21.62-$52.69-$261.87
EPS-$0.004-$0.004-$0.004-$0.003
Diluted EPS-$0.004-$0.004-$0.004-$0.003
Weighted Avg Shares Outstanding$1.13B$905.57M$828.89M$780.26M
Weighted Avg Shares Outstanding (Diluted)$1.13B$905.57M$828.89M$780.26M

Financial performance has remained strong, with revenue growing from $9843.00 in Q2 2023 to $309466.00 in Q4 2024. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$3.97M in Q4 2024, holding a steady -1281% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$4.01M. Net income dropped to -$3.94M, keeping EPS at -$0.004. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;